CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs. RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases,. ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the 11 Best Performing IPOs in the Last 2 Years. The stock’s price target is raised following a strong second quarter and FDA approval for Tempus Pixel. Tempus AI Surges Since IPO as FDA Clearance Boosts Growth Outlook Copyright: argus456 / 123RF Stock Photo On August 08, 2025, Tempus AI, Inc. (NASDAQ:TEM) reported a second-quarter 2025 revenue of $314.6 million, an increase of 89.6%. The growth was attributed to a 115% increase in Genomics revenue driven by stron ...

公司业务模式与收入构成 - 公司被指控将自己标榜为人工智能企业 但缺乏从人工智能解决方案产生重大收入的历史[1] - 公司大部分收入来自收购活动、基因组测试及数据许可协议 而非核心人工智能业务[1] - 公司强调与长期客户阿斯利康的合作关系 并宣布通过公司与阿斯利康及Pathos AI的合资企业扩大合作[1] 市场扩张与合作伙伴关系 - 公司宣布与软银成立合资企业 以此作为进入日本市场并推动收入增长的方式[1] - 公司声称被收购目标Ambry Genetics具有高收入潜力 并强调其与医疗保健提供商的稳固关系推动了加速增长[1] 信息披露与法律调查 - 公司内部人士多次声称其与生命科学公司的数据许可协议合同价值和质量安全且不断扩大[1] - 股东诉讼律师事务所正在调查公司某些高管及董事是否违反了对股东的信义义务[1]

Artificial intelligence (AI) has been the market’s favorite catalyst over the past year, fueling rallies across everything from chipmakers to cloud software stocks. But one of the more surprising success stories has come from healthcare, a sector not usually known for flashy AI-driven growth. That’s where Tempus AI (TEM) enters the picture. Going public just last year, Tempus is already experiencing sharp revenue gains and notable improvements in the bottom line, unlike the typical biotech IPOs that often ...

In this article, we will be looking at the 11 best performing IPOs in the last 2 years.The market environment has been heavily influenced by the changes in monetary policies and global economic uncertainties. Sticky consumer price inflation had to be weighed against the U.S. labor market, which has been going soft recently, while investors are looking forward to a potential first rate cut this week from the Federal Reserve. According to Reuters, futures currently have about 70 basis points of cuts priced ov ...

投资组合调整 - 公司买入Advanced Micro Devices Inc 25,899股 价值约410万美元[2] - 公司买入Bullish Inc 161,183股 价值约830万美元[3] - 公司卖出Tempus AI Inc 167,598股 价值约1,460万美元[6] - 公司买入Figma Inc 109,678股 价值约590万美元[7] Advanced Micro Devices投资分析 - 以每股160.46美元价格买入AMD股票[2] - 美国政府投资英特尔可能造成半导体行业效率低下[2] - Benzinga股票排名显示AMD价值处于第9百分位数[9] Bullish Inc投资分析 - 加密货币平台Bullish近期通过美国IPO筹集11亿美元资金[4] - Rosenblatt给予买入评级 认为政治顺风和美国上市是主要催化剂[4] - 摩根大通给予中性评级 指出机构增长但业务规模仍不足[4] - 上周已购买190万美元Bullish股票[5] Tempus AI减持分析 - 以每股87.04美元价格卖出TEM股票[6] - 公司近期获得FDA对其AI心脏成像平台的批准[6] - 上周已卖出520万美元Tempus AI股票[6] Figma Inc增持分析 - 以每股53.67美元价格增持FIG股票[7] - 本月早期已购买590万美元Figma股票 上周再增持480万美元[7] - 持续投资显示对公司长期增长前景的信心 尽管近期盈利令人失望[7] 其他重要交易 - ARKF购买26,365股Airbnb Inc[10] - ARKG收购62,313股Arcturus Therapeutics[10] - ARKK购买615,831股Intellia Therapeutics[10] - ARKK买入69,889股CRISPR Therapeutics[10] - ARKK收购81,777股Beam Therapeutics[10] - ARKK卖出9,151股Roku Inc[10]

公司业务进展 - 公司开发部署一系列先进放射学算法 帮助医生提供更精准个性化医疗服务[1] - 公司AI心脏成像平台Tempus Pixel获得FDA 510(k)许可 可生成T1和T2内联图谱用于心脏组织特征分析[2][10] - 平台提供心脏磁共振图像高级查看和自动报告功能 改善血流可视化 功能分析和组织表征的效率与准确性[3] - 通过快速分析扫描图像 突出显示细微异常 生成可操作的见解来增强医学影像能力[3] - 2022年收购Arterys 将其AI驱动的影像数据分析工具整合至平台 覆盖肺部CT扫描 胸部X光到心脏MRI等多种影像数据类型[4] 市场前景与行业动态 - AI放射学市场预计到2035年将增长至157亿美元 2025-2035年复合年增长率为1956%[2] - 同业公司GE HealthCare推出Voluson Performance系列 配备智能AI和自动化工具 简化测量 解剖识别和报告流程[5] - GE HealthCare计划收购icometrix 将其AI脑成像分析平台与MRI系统集成[6] - NANO-X IMAGING LTD多源NanoxARC系统获得CE认证 包括云端基础设施NanoxCLOUD[7] - NanoxAI子公司获得FDA 510(k)许可 其HealthCCSng V20可通过常规CT扫描自动测量冠状动脉钙化[8] 财务表现与估值 - 公司年内股价上涨1522% 超越行业285%的涨幅和标普500指数128%的涨幅[9] - 公司远期12个月市销率为1002倍 高于行业平均592倍[11] - 2025年每股亏损预估在过去30天内下调3美分 当前季度(2025年9月)预估为-016美元 下一季度(2025年12月)为-008美元 当前年度(2025年12月)为-069美元[12]

Tempus AI stock price surged to a record high on Wednesday after the healthcare-focused artificial intelligence company announced a major breakthrough from the Food and Drug Administration (FDA). It j... ...

股价表现 - Tempus AI股价单日大涨13.6%至88.78美元 成交量显著高于正常水平 过去四周累计涨幅达12.3% [1] - 同业公司Outset Medical股价单日上涨4.5%至14.15美元 过去一个月累计涨幅2.5% [4] 监管进展 - 美国FDA批准公司AI心脏成像平台Tempus Pixel的升级版本 新增生成T1和T2内联图谱功能 增强心脏MR图像分析能力 [2] 财务预期 - 预计季度营收3.2688亿美元 同比增长80.7% 季度每股亏损预计0.16美元 同比改善36% [3] - Outset Medical预计季度每股亏损0.64美元 同比大幅改善89.1% [5] 分析师预期 - 公司未来30天共识EPS预期维持不变 同业Outset Medical的EPS预期在过去一个月同样保持稳定 [4][5] - 公司当前获Zacks评级3级(持有) Outset Medical获Zacks评级2级(买入) [4][5]

We recently published 10 Stocks Investors Are Gobbling Up. Tempus AI, Inc. (NASDAQ:TEM) is one of the best performers on Thursday. Shares of Tempus AI surged to a seven-month high on Thursday, jumping 13.59 percent to close at $88.78 apiece as investors cheered the Food and Drug Administration’s (FDA) green light for the updated version of Tempus Pixel, its AI-powered cardiac imaging platform. During the session, the stock touched a high of $91.06, or just 39 cents shy of its 52-week high of $91.45. Tem ...